Will AstraZeneca plc, Serco Group plc And RSA insurance Group plc Ever Deliver On Their Turnaround Potential?

Should you buy or sell these 3 stocks? AstraZeneca plc (LON: AZN), Serco Group plc (LON: SRP) and RSA insurance Group plc (LON: RSA).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in insurance company RSA (LSE: RSA) were given a boost today after it beat market expectations to post a rise in operating profit of 43%. As a result of this, its shares are up by over 7%, with the company stating that the turnaround phase of its Action Plan is now largely complete.

With RSA’s underwriting profit rising by 437%, 2015 represented a record year for the business despite the major impact of floods in the UK. And with there being the prospect for substantial further improvement in underwriting profits moving forward, it would be of little surprise for RSA’s dividend to continue to rise at a brisk pace following today’s announcement that the final dividend has increased by 250% to 7p per share. This puts RSA on a yield of 2.4%, and with dividends forecast to rise during the next two financial years, RSA has a forward yield of 4.7%.

Clearly, RSA’s financial performance is on the up and this represents a superb turnaround from the difficulties it has experienced in recent years. While it’s often said that some turnarounds never turn, RSA is proof that with a sound strategy it’s possible to deliver improved financial performance. With its shares trading on a price to earnings growth (PEG) ratio of just 1.4, it seems to be a strong buy at the present time.

Incomplete turnaround

Also reporting today was support services company Serco (LSE: SRP). Like RSA, it has endured a challenging period, but today’s results show that it’s delivering improved performance. As well as underlying trading profit being ahead of market expectations (£96m versus guidance of £90m), Serco’s pipeline of new bid opportunities has increased by £1.5bn to £6.5bn. This bodes well for its future sales growth and alongside cost reductions of £330m, could have a positive impact on profitability in the medium-to-long term.

Despite this, Serco is still forecasting falling sales and profit in 2016 due to disposals and also contract attrition. Therefore, its turnaround process remains incomplete and with it trading on a price-to-earnings (P/E) ratio of 68.7, it may be prudent to await further positive news flow before buying a slice of it.

Drug pipeline

Meanwhile, AstraZeneca (LSE: AZN) is also in the midst of its own turnaround process. This is centred on improving its drug pipeline through the purchase of a number of smaller companies and treatments as it seeks to arrest the decline in profitability that has seen its earnings fall by over 40% in the last four years.

Clearly, AstraZeneca is still some way off delivering positive bottom line growth. Its forecasts for 2016 and 2017 aren’t particularly encouraging, with a decline in net profit of 10% expected this year and a marginal increase in earnings due for next year.

However, for long-term investors it remains a very strong buy since it has the financial firepower to change its business through vast M&A activity so as to deliver multiple blockbuster drugs in the coming years. And with it trading on a P/E ratio of just 15.1, it appears to offer good value for money based on its long-term potential.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

How I’d invest my first £20k ISA to target £4,900 a year from dividend shares

Looking for dividend shares in a new Stocks and Shares ISA, and want diversification too? Here's how I'd go about…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »